The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995

Radiotherapy and Oncology

Volumn 96, Issue 1, 2010, Pages 6-12

  Thames, Howard D ^a   Kuban, Deborah ^a   Levy, Larry B ^a   Horwitz, Eric M ^b   Kupelian, Patrick ^c   Martinez, Alvaro ^d   Michalski, Jeffrey ^e   Pisansky, Thomas ^f   Sandler, Howard ^g   Shipley, William ^h   Zelefsky, Michael ⁱ   Zietman, Anthony ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Radiation; Time factor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CENTER; CANCER RADIOTHERAPY; CELL PROLIFERATION; FEMALE; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; COHORT STUDIES; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77953962354     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.03.020     Document Type: Article

References (30)

1. Lai P.P., Perez C.A., Shapiro S.J., et al. Carcinoma of the prostate stage B and C: lack of influence of duration of radiotherapy on tumor control and treatment morbidity. Int J Radiat Oncol Biol Phys 19 (1990) 561-568
2. Lai P.P., Pilepich M.V., Krall J.M., et al. The effect of overall time on the outcome of definitive radiotherapy for localized prostate carcinoma: the radiation therapy oncology group 75-06 and 77-06 experiences. Int J Radiat Oncol Biol Phys 21 (1991) 925-933
3. Amdur R.J., Parsons J.T., Fitzgerald L.T., et al. The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. Int J Radiat Oncol Biol Phys 19 (1990) 1377-1382
4. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
5. Duchesne G.M., and Peters L.J. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys 44 (1999) 747-748
6. Fowler J., Chappell R., and Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
7. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
8. Wang Z., Guerrero M., and Li X.A. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
9. Williams S.G., Taylor J.M.G., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
10. Haustermans K.M., Hofland I., van Poppel H., et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 1067-1070
11. Miles E.F., and Lee W.R. Hypofractionation for prostate cancer: a critical review. Sem Radiat Oncol 18 (2008) 41-47
12. D'Souza W.D., and Thames H.D. Is the α/β ratio for prostate cancer low?. Int J Radiat Oncol Biol Phys 51 (2001) 1-3
13. Thames H.D., D'Souza W.D., and Kuban D.A. Dual radiobiological interpretations of retrospective clinical data: the time factor. Int J Radiat Biol 79 (2003) 503-509
14. d'Ambrosio D.J., Li T., Horwitz E.M., Chen D.Y.T., et al. Does treatment duration affect outcome after radiotherapy for prostate cancer?. Int J Radiat Oncol Biol Phys 72 (2008) 1402-1407
15. Roach M., Hanks G., Thames H.D., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
16. Pollack A., Li T., Buyyounouski M., and Horwitz E. Hypofractionation for prostate cancer: interim results of a randomized trial. Int J Radiat Oncol Biol Phys 75 (2009) S81
17. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
18. Jereczek-Fossa B.A., and Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 84 (2007) 197-215
19. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Oncol 23 (1984) 379-391
20. Bentzen S.M., and Joiner M.C. The linear-quadratic approach in clinical practice. In: Joiner M.C., and van der Kogel A.J. (Eds). Basic clinical radiobiology. 4th ed. (2009), Arnold, London 120-134
21. Bentzen S.M., and Ritter M.A. The α/β ratio for prostate cancer: what is it, really?. Radiother Oncol 76 (2005) 1-3
22. Withers H.R., Taylor J.M., and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
23. Roberts S.A., Hendry J.H., Brewster A.E., and Slevin N.J. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. Br J Radiol 67 (1994) 790-794
24. Withers H.R., Peters L.J., Taylor J.M., et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 33 (1995) 549-562
25. Hendry J.H., Bentzen S.M., Dale R.G., et al. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol 8 (1996) 297-307
26. Koukourakis M., Hlouverakis G., Kosma L., et al. The impact of overall time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 34 (1996) 315-322
27. Robertson C., Robertson A.G., Hendry J.H., et al. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 40 (1998) 319-329
28. Hinata H., Inakoshi H., Sakai K., et al. Estimation of time parameter of LQ-model in fractionated radiotherapy of medulloblastoma. Radiat Med 19 (2001) 61-70
29. Geh J.I., Bond S.J., Bentzen S.M., and Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 78 (2006) 236-244
30. Valdagni R., Italia C., Montanaro P., Lanceni A., Lattuada P., Magnani T., et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 75 (2005) 74-82